Furthermore, valproic acid (VPA, the first-line drug for epilepsy treatment in clinical practice) also inhibits CREB activity by abrogating excessive CREB expression in children with epilepsy, as compared to that in healthy controls [65], although VPA does not affect CREB DNA binding activity in vitro [66]. The gene discussed is CREB1; the disease is epilepsy.